Get Cash Back and $0 Commissions
+ The Power of TradeStation
PRNewswire 25-Jul-2024 7:36 AM
NORTH CHICAGO, Ill., July 25, 2024 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the second quarter ended June 30, 2024.
"Our business continues to perform exceptionally well, with second quarter results meaningfully ahead of our expectations," said Robert A. Michael, chief executive officer, AbbVie. "Based upon the significant momentum of our ex-Humira growth platform, our continued investments in the business and our pipeline progress, we are very well positioned to deliver our top-tier long-term outlook."
Second-Quarter Results
Note: "Operational" comparisons are presented at constant currency rates that reflect comparative local currency net revenues at the prior year's foreign exchange rates.
Recent Events
Full-Year 2024 Outlook
AbbVie is raising its adjusted diluted EPS guidance for the full year 2024 from $10.61 - $10.81 to $10.71 - $10.91, which includes an unfavorable impact of $0.60 per share related to acquired IPR&D and milestones expense incurred year-to-date through the second quarter 2024. The company's 2024 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones that may be incurred beyond the second quarter of 2024, as both cannot be reliably forecasted.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience and eye care - and products and services across our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on X (formerly Twitter), Facebook, Instagram, YouTube or LinkedIn.
Conference Call
AbbVie will host an investor conference call today at 8:00 a.m. Central Time to discuss our second-quarter performance. The call will be webcast through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the call will be available after 11:00 a.m. Central Time.
Non-GAAP Financial Results
Financial results for 2024 and 2023 are presented on both a reported and a non-GAAP basis. Reported results were prepared in accordance with GAAP and include all revenue and expenses recognized during the period. Non-GAAP results adjust for certain non-cash items and for factors that are unusual or unpredictable, and exclude those costs, expenses, and other specified items presented in the reconciliation tables later in this release. AbbVie's management believes non-GAAP financial measures provide useful information to investors regarding AbbVie's results of operations and assist management, analysts, and investors in evaluating the performance of the business. Non-GAAP financial measures should be considered in addition to, and not as a substitute for, measures of financial performance prepared in accordance with GAAP.
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks related to the proposed acquisition of Cerevel Therapeutics, including the possibility that the acquisition may not be consummated on the anticipated timeframe or at all, risks related to the ability to realize the anticipated benefits of the proposed acquisition on the anticipated timeframe or at all, risks that the costs to consummate the proposed acquisition or to obtain the anticipated benefits of the proposed acquisition could be greater than expected, the risk that an event occurs that could give rise to the right of AbbVie, on the one hand, or Cerevel Therapeutics, on the other hand, to terminate the acquisition agreement for such transaction, the risk that the business will not be integrated successfully, disruption from the proposed acquisition making it more difficult to maintain business and operational relationships, the diversion of management's attention from ongoing business operations and opportunities, negative effects of the consummation of the proposed acquisition on business or employee relationships or the market price of the Company's common stock and/or operating results, significant transaction costs, the assumption of unknown liabilities, the risk of litigation and/or regulatory actions related to the proposed acquisition of Cerevel Therapeutics's business, risks related to the financing of the proposed acquisition, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's and Cerevel Therapeutics's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2023 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information; Item 1A, "Risk Factors," of Cerevel Therapeutics's 2023 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that Cerevel Therapeutics subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
AbbVie Inc. Key Product Revenues Quarter Ended June 30, 2024 (Unaudited) | |||||||||||||||
% Change vs. 2Q23 | |||||||||||||||
Net Revenues (in millions) | Reported | Operationala | |||||||||||||
U.S. | Int'l. | Total | U.S. | Int'l. | Total | Int'l. | Total | ||||||||
NET REVENUES | $11,106 | $3,356 | $14,462 | 3.6 % | 6.8 % | 4.3 % | 12.7 % | 5.6 % | |||||||
Immunology | 5,717 | 1,254 | 6,971 | (0.2) | 15.9 | 2.3 | 23.5 | 3.5 | |||||||
Humira | 2,360 | 454 | 2,814 | (31.6) | (18.9) | (29.8) | (12.5) | (28.9) | |||||||
Skyrizi | 2,340 | 387 | 2,727 | 43.2 | 55.5 | 44.8 | 61.8 | 45.6 | |||||||
Rinvoq | 1,017 | 413 | 1,430 | 57.9 | 51.1 | 55.8 | 62.6 | 59.2 | |||||||
Oncology | 1,037 | 597 | 1,634 | 11.3 | 9.3 | 10.5 | 13.8 | 12.2 | |||||||
Imbruvicab | 595 | 238 | 833 | (10.6) | (1.4) | (8.2) | (1.4) | (8.2) | |||||||
Venclexta | 300 | 337 | 637 | 12.8 | 10.4 | 11.5 | 18.4 | 15.8 | |||||||
Elahere | 128 | — | 128 | n/m | n/m | n/m | n/m | n/m | |||||||
Epkinlyc | 14 | 22 | 36 | >100.0 | n/m | >100.0 | n/m | >100.0 | |||||||
Aesthetics | 863 | 527 | 1,390 | 4.4 | (5.4) | 0.5 | 0.4 | 2.8 | |||||||
Botox Cosmetic | 450 | 279 | 729 | 7.1 | 5.2 | 6.4 | 10.9 | 8.6 | |||||||
Juvederm Collection | 138 | 205 | 343 | 10.4 | (15.6) | (6.8) | (10.0) | (3.1) | |||||||
Other Aesthetics | 275 | 43 | 318 | (2.3) | (11.7) | (3.6) | (4.1) | (2.5) | |||||||
Neuroscience | 1,895 | 267 | 2,162 | 14.9 | 13.5 | 14.7 | 17.3 | 15.2 | |||||||
Botox Therapeutic | 669 | 145 | 814 | 8.9 | 7.9 | 8.7 | 13.0 | 9.6 | |||||||
Vraylar | 773 | 1 | 774 | 17.5 | 68.8 | 17.6 | 69.2 | 17.6 | |||||||
Duodopa | 23 | 90 | 113 | (2.6) | (3.2) | (3.1) | (1.7) | (1.9) | |||||||
Ubrelvy | 227 | 4 | 231 | 16.6 | 81.6 | 17.5 | 82.3 | 17.5 | |||||||
Qulipta | 146 | 4 | 150 | 52.8 | >100.0 | 56.3 | >100.0 | 56.3 | |||||||
Other Neuroscience | 57 | 23 | 80 | (10.1) | >100.0 | 16.6 | >100.0 | 17.5 | |||||||
Eye Care | 239 | 294 | 533 | (21.8) | (4.7) | (13.3) | 0.2 | (10.9) | |||||||
Ozurdex | 35 | 89 | 124 | 4.2 | 4.6 | 4.5 | 9.5 | 8.0 | |||||||
Lumigan/Ganfort | 42 | 61 | 103 | (15.8) | (11.2) | (13.2) | (8.1) | (11.4) | |||||||
Alphagan/Combigan | 13 | 36 | 49 | (59.5) | 9.1 | (23.7) | 20.5 | (17.8) | |||||||
Restasis | 18 | 14 | 32 | (77.3) | (18.9) | (67.0) | (14.5) | (66.2) | |||||||
Other Eye Care | 131 | 94 | 225 | 18.9 | (10.1) | 4.8 | (6.1) | 6.7 | |||||||
Other Key Products | 750 | 212 | 962 | 0.9 | 4.1 | 1.6 | 8.8 | 2.6 | |||||||
Mavyret | 167 | 202 | 369 | (13.2) | 3.8 | (4.7) | 8.8 | (2.2) | |||||||
Creon | 372 | — | 372 | 32.1 | n/m | 32.1 | n/m | 32.1 | |||||||
Linzess/Constella | 211 | 10 | 221 | (21.7) | 9.1 | (20.7) | 9.2 | (20.7) |
a | "Operational" comparisons are presented at constant currency rates that reflect comparative local currency net revenues at the |
b | Reflects profit sharing for Imbruvica international revenues. |
c | Epkinly U.S. revenues reflect profit sharing. International revenues reflect product revenues as well as profit sharing from certain |
n/m = not meaningful |
AbbVie Inc. Key Product Revenues Six Months Ended June 30, 2024 (Unaudited) | |||||||||||||||
% Change vs. 6M23 | |||||||||||||||
Net Revenues (in millions) | Reported | Operationala | |||||||||||||
U.S. | Int'l. | Total | U.S. | Int'l. | Total | Int'l. | Total | ||||||||
NET REVENUES | $20,147 | $6,625 | $26,772 | 1.1 % | 7.4 % | 2.6 % | 12.1 % | 3.7 % | |||||||
Immunology | 9,869 | 2,473 | 12,342 | (3.9) | 15.9 | (0.5) | 22.0 | 0.6 | |||||||
Humira | 4,131 | 953 | 5,084 | (35.5) | (17.3) | (32.7) | (12.1) | (31.9) | |||||||
Skyrizi | 3,996 | 739 | 4,735 | 44.1 | 57.3 | 46.0 | 61.7 | 46.6 | |||||||
Rinvoq | 1,742 | 781 | 2,523 | 59.3 | 53.0 | 57.3 | 62.7 | 60.4 | |||||||
Oncology | 2,004 | 1,173 | 3,177 | 9.3 | 10.6 | 9.8 | 14.0 | 11.0 | |||||||
Imbruvicab | 1,205 | 466 | 1,671 | (7.5) | (3.2) | (6.4) | (3.2) | (6.4) | |||||||
Venclexta | 581 | 670 | 1,251 | 9.5 | 15.8 | 12.8 | 22.0 | 16.0 | |||||||
Elaherec | 192 | — | 192 | n/m | n/m | n/m | n/m | n/m | |||||||
Epkinlyd | 26 | 37 | 63 | >100.0 | n/m | >100.0 | n/m | >100.0 | |||||||
Aesthetics | 1,639 | 1,000 | 2,639 | 2.1 | (7.3) | (1.7) | (2.4) | 0.3 | |||||||
Botox Cosmetic | 839 | 523 | 1,362 | 1.2 | 1.6 | 1.3 | 6.2 | 3.1 | |||||||
Juvederm Collection | 244 | 396 | 640 | (1.2) | (16.8) | (11.5) | (11.9) | (8.3) | |||||||
Other Aesthetics | 556 | 81 | 637 | 5.2 | (8.1) | 3.3 | (1.8) | 4.2 | |||||||
Neuroscience | 3,609 | 518 | 4,127 | 16.0 | 10.7 | 15.3 | 13.1 | 15.6 | |||||||
Botox Therapeutic | 1,280 | 282 | 1,562 | 6.6 | 5.9 | 6.5 | 9.7 | 7.2 | |||||||
Vraylar | 1,465 | 3 | 1,468 | 20.3 | 96.7 | 20.4 | 96.3 | 20.4 | |||||||
Duodopa | 48 | 180 | 228 | (2.6) | (3.0) | (2.9) | (2.8) | (2.7) | |||||||
Ubrelvy | 424 | 10 | 434 | 23.1 | >100.0 | 24.6 | >100.0 | 24.6 | |||||||
Qulipta | 274 | 7 | 281 | 69.8 | >100.0 | 73.2 | >100.0 | 73.2 | |||||||
Other Neuroscience | 118 | 36 | 154 | (14.6) | >100.0 | 4.1 | >100.0 | 4.7 | |||||||
Eye Care | 466 | 605 | 1,071 | (25.6) | 1.3 | (12.5) | 5.1 | (10.6) | |||||||
Ozurdex | 69 | 186 | 255 | (5.4) | 15.6 | 9.0 | 18.8 | 11.2 | |||||||
Lumigan/Ganfort | 71 | 123 | 194 | (37.4) | (9.4) | (22.2) | (7.3) | (21.0) | |||||||
Alphagan/Combigan | 28 | 80 | 108 | (53.4) | 5.0 | (20.6) | 12.8 | (16.2) | |||||||
Restasis | 62 | 27 | 89 | (61.0) | (11.4) | (53.1) | (6.5) | (52.3) | |||||||
Other Eye Care | 236 | 189 | 425 | 7.1 | (2.7) | 2.5 | 1.0 | 4.2 | |||||||
Other Key Products | 1,436 | 426 | 1,862 | (2.3) | 5.2 | (0.7) | 8.8 | 0.1 | |||||||
Mavyret | 311 | 407 | 718 | (14.4) | 5.0 | (4.4) | 8.9 | (2.4) | |||||||
Creon | 657 | — | 657 | 12.0 | n/m | 12.0 | n/m | 12.0 | |||||||
Linzess/Constella | 468 | 19 | 487 | (10.0) | 9.1 | (9.4) | 8.0 | (9.4) |
a | "Operational" comparisons are presented at constant currency rates that reflect comparative local currency net revenues at the |
b | Reflects profit sharing for Imbruvica international revenues. |
c | Reflects partial year Elahere revenue based on the February 12, 2024 close date of the ImmunoGen acquisition. |
d | Epkinly U.S. revenues reflect profit sharing. International revenues reflect product revenues as well as profit sharing from certain |
n/m = not meaningful |
AbbVie Inc. Consolidated Statements of Earnings (Unaudited) | |||||||
(in millions, except per share data) | Second Quarter Ended June 30 | Six Months Ended June 30 | |||||
2024 | 2023 | 2024 | 2023 | ||||
Net revenues | $ 14,462 | $ 13,865 | $ 26,772 | $ 26,090 | |||
Cost of products sold | 4,202 | 4,240 | 8,296 | 8,226 | |||
Selling, general and administrative | 3,377 | 3,268 | 6,692 | 6,307 | |||
Research and development | 1,948 | 1,733 | 3,887 | 4,025 | |||
Acquired IPR&D and milestones | 937 | 280 | 1,101 | 430 | |||
Other operating income | — | (169) | — | (179) | |||
Total operating costs and expenses | 10,464 | 9,352 | 19,976 | 18,809 | |||
Operating earnings | 3,998 | 4,513 | 6,796 | 7,281 | |||
Interest expense, net | 506 | 454 | 959 | 908 | |||
Net foreign exchange loss | 1 | 37 | 5 | 72 | |||
Other expense, net | 1,345 | 1,412 | 1,931 | 3,216 | |||
Earnings before income tax expense | 2,146 | 2,610 | 3,901 | 3,085 | |||
Income tax expense | 773 | 583 | 1,156 | 817 | |||
Net earnings | 1,373 | 2,027 | 2,745 | 2,268 | |||
Net earnings attributable to noncontrolling interest | 3 | 3 | 6 | 5 | |||
Net earnings attributable to AbbVie Inc. | $ 1,370 | $ 2,024 | $ 2,739 | $ 2,263 | |||
Diluted earnings per share attributable to AbbVie Inc. | $ 0.77 | $ 1.14 | $ 1.53 | $ 1.26 | |||
Adjusted diluted earnings per sharea | $ 2.65 | $ 2.91 | $ 4.96 | $ 5.37 | |||
Weighted-average diluted shares outstanding | 1,771 | 1,771 | 1,772 | 1,773 |
a | Refer to the Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for further details. |
AbbVie Inc. Reconciliation of GAAP Reported to Non-GAAP Adjusted Information (Unaudited) | |||||
1. Specified items impacted results as follows: | |||||
Quarter Ended June 30, 2024 | |||||
(in millions, except per share data) | Earnings | Diluted | |||
Pre-tax | After-taxa | EPS | |||
As reported (GAAP) | $ 2,146 | $ 1,370 | $ 0.77 | ||
Adjusted for specified items: | |||||
Intangible asset amortization | 1,947 | 1,651 | 0.93 | ||
Acquisition and integration costs | 145 | 125 | 0.07 | ||
Change in fair value of contingent consideration | 1,476 | 1,438 | 0.81 | ||
Other | 90 | 126 | 0.07 | ||
As adjusted (non-GAAP) | $ 5,804 | $ 4,710 | $ 2.65 |
a Represents net earnings attributable to AbbVie Inc. |
Acquisition and integration costs primarily reflect costs related to the ImmunoGen acquisition. |
Reported GAAP earnings and adjusted non-GAAP earnings for the three months ended June 30, 2024 included acquired IPR&D |
2. The impact of the specified items by line item was as follows: | |||||||
Quarter Ended June 30, 2024 | |||||||
(in millions) | Cost of | SG&A | R&D | Other | |||
As reported (GAAP) | $ 4,202 | $ 3,377 | $ 1,948 | $ 1,345 | |||
Adjusted for specified items: | |||||||
Intangible asset amortization | (1,947) | — | — | — | |||
Acquisition and integration costs | (79) | (35) | (31) | — | |||
Change in fair value of contingent consideration | — | — | — | (1,476) | |||
Other | (41) | (27) | — | (22) | |||
As adjusted (non-GAAP) | $ 2,135 | $ 3,315 | $ 1,917 | $ (153) |
3. The adjusted tax rate for the second quarter of 2024 was 18.8 percent, as detailed below: | |||||
Quarter Ended June 30, 2024 | |||||
(dollars in millions) | Pre-tax | Income taxes | Tax rate | ||
As reported (GAAP) | $ 2,146 | $ 773 | 36.0 % | ||
Specified items | 3,658 | 318 | 8.7 % | ||
As adjusted (non-GAAP) | $ 5,804 | $ 1,091 | 18.8 % |
AbbVie Inc. Reconciliation of GAAP Reported to Non-GAAP Adjusted Information (Unaudited) | |||||
1. Specified items impacted results as follows: | |||||
Quarter Ended June 30, 2023 | |||||
(in millions, except per share data) | Earnings | Diluted | |||
Pre-tax | After-taxa | EPS | |||
As reported (GAAP) | $ 2,610 | $ 2,024 | $ 1.14 | ||
Adjusted for specified items: | |||||
Intangible asset amortization | 2,070 | 1,727 | 0.97 | ||
Acquisition and integration costs | (83) | (94) | (0.05) | ||
Change in fair value of contingent consideration | 1,552 | 1,518 | 0.85 | ||
Other | (1) | — | — | ||
As adjusted (non-GAAP) | $ 6,148 | $ 5,175 | $ 2.91 |
a Represents net earnings attributable to AbbVie Inc. |
Acquisition and integration costs reflect integration costs related to the Allergan acquisition, including a one-time gain of $169 |
Reported GAAP earnings and adjusted non-GAAP earnings for the three months ended June 30, 2023 included acquired IPR&D |
2. The impact of the specified items by line item was as follows: | |||||||||
Quarter Ended June 30, 2023 | |||||||||
(in millions) | Cost of | SG&A | R&D | Other | Other | ||||
As reported (GAAP) | $ 4,240 | $ 3,268 | $ 1,733 | $ (169) | $ 1,412 | ||||
Adjusted for specified items: | |||||||||
Intangible asset amortization | (2,070) | — | — | — | — | ||||
Acquisition and integration costs | (33) | (50) | (3) | 169 | — | ||||
Change in fair value of contingent consideration | — | — | — | — | (1,552) | ||||
Other | (20) | — | — | — | 21 | ||||
As adjusted (non-GAAP) | $ 2,117 | $ 3,218 | $ 1,730 | $ — | $ (119) |
3. The adjusted tax rate for the second quarter of 2023 was 15.8 percent, as detailed below: | |||||
Quarter Ended June 30, 2023 | |||||
(dollars in millions) | Pre-tax | Income taxes | Tax rate | ||
As reported (GAAP) | $ 2,610 | $ 583 | 22.3 % | ||
Specified items | 3,538 | 387 | 10.9 % | ||
As adjusted (non-GAAP) | $ 6,148 | $ 970 | 15.8 % |
AbbVie Inc. Reconciliation of GAAP Reported to Non-GAAP Adjusted Information (Unaudited) | |||||
1. Specified items impacted results as follows: | |||||
Six Months Ended June 30, 2024 | |||||
(in millions, except per share data) | Earnings | Diluted | |||
Pre-tax | After-taxa | EPS | |||
As reported (GAAP) | $ 3,901 | $ 2,739 | $ 1.53 | ||
Adjusted for specified items: | |||||
Intangible asset amortization | 3,838 | 3,254 | 1.84 | ||
Acquisition and integration costs | 656 | 611 | 0.34 | ||
Change in fair value of contingent consideration | 2,136 | 2,081 | 1.17 | ||
Other | 111 | 145 | 0.08 | ||
As adjusted (non-GAAP) | $ 10,642 | $ 8,830 | $ 4.96 |
a Represents net earnings attributable to AbbVie Inc. |
Acquisition and integration costs primarily reflect costs related to the ImmunoGen acquisition. |
Reported GAAP earnings and adjusted non-GAAP earnings for the six months ended June 30, 2024 included acquired IPR&D |
2. The impact of the specified items by line item was as follows: | |||||||||
Six Months Ended June 30, 2024 | |||||||||
(in millions) | Cost of | SG&A | R&D | Interest | Other | ||||
As reported (GAAP) | $ 8,296 | $ 6,692 | $ 3,887 | $ 959 | $ 1,931 | ||||
Adjusted for specified items: | |||||||||
Intangible asset amortization | (3,838) | — | — | — | — | ||||
Acquisition and integration costs | (158) | (315) | (159) | (24) | — | ||||
Change in fair value of contingent consideration | — | — | — | — | (2,136) | ||||
Other | (57) | (30) | — | — | (24) | ||||
As adjusted (non-GAAP) | $ 4,243 | $ 6,347 | $ 3,728 | $ 935 | $ (229) |
3. The adjusted tax rate for the first six months of 2024 was 17.0 percent, as detailed below: | |||||
Six Months Ended June 30, 2024 | |||||
(dollars in millions) | Pre-tax | Income taxes | Tax rate | ||
As reported (GAAP) | $ 3,901 | $ 1,156 | 29.6 % | ||
Specified items | 6,741 | 650 | 9.6 % | ||
As adjusted (non-GAAP) | $ 10,642 | $ 1,806 | 17.0 % |
AbbVie Inc. Reconciliation of GAAP Reported to Non-GAAP Adjusted Information (Unaudited) | |||||
1. Specified items impacted results as follows: | |||||
Six Months Ended June 30, 2023 | |||||
(in millions, except per share data) | Earnings | Diluted | |||
Pre-tax | After-taxa | EPS | |||
As reported (GAAP) | $ 3,085 | $ 2,263 | $ 1.26 | ||
Adjusted for specified items: | |||||
Intangible asset amortization | 4,018 | 3,373 | 1.90 | ||
Intangible asset impairment | 710 | 629 | 0.35 | ||
Acquisition and integration costs | (22) | (39) | (0.02) | ||
Change in fair value of contingent consideration | 3,424 | 3,340 | 1.88 | ||
Other | 16 | (6) | — | ||
As adjusted (non-GAAP) | $ 11,231 | $ 9,560 | $ 5.37 |
a Represents net earnings attributable to AbbVie Inc. |
Acquisition and integration costs primarily reflect integration costs related to the Allergan acquisition, including a one-time gain |
Reported GAAP earnings and adjusted non-GAAP earnings for the six months ended June 30, 2023 included acquired IPR&D |
2. The impact of the specified items by line item was as follows: | |||||||||
Six Months Ended June 30, 2023 | |||||||||
(in millions) | Cost of | SG&A | R&D | Other | Other | ||||
As reported (GAAP) | $ 8,226 | $ 6,307 | $ 4,025 | $ (179) | $ 3,216 | ||||
Adjusted for specified items: | |||||||||
Intangible asset amortization | (4,018) | — | — | — | — | ||||
Intangible asset impairment | (80) | — | (630) | — | — | ||||
Acquisition and integration costs | (48) | (94) | (5) | 169 | — | ||||
Change in fair value of contingent consideration | — | — | — | — | (3,424) | ||||
Other | (32) | (11) | (3) | 10 | 20 | ||||
As adjusted (non-GAAP) | $ 4,048 | $ 6,202 | $ 3,387 | $ — | $ (188) |
3. The adjusted tax rate for the first six months of 2023 was 14.8 percent, as detailed below: | |||||
Six Months Ended June 30, 2023 | |||||
(dollars in millions) | Pre-tax | Income taxes | Tax rate | ||
As reported (GAAP) | $ 3,085 | $ 817 | 26.5 % | ||
Specified items | 8,146 | 849 | 10.4 % | ||
As adjusted (non-GAAP) | $ 11,231 | $ 1,666 | 14.8 % |
View original content to download multimedia:https://www.prnewswire.com/news-releases/abbvie-reports-second-quarter-2024-financial-results-302205992.html
SOURCE AbbVie